Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) should contact The Gross Law Firm about pending Class Action - SRPT

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations and Class Period - The class period for the allegations spans from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [3]. - Specific claims include significant safety risks associated with ELEVIDYS, failure of trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [5].